JP2017525340A - 治療的用途のためのフコシル化細胞の製造および凍結保存 - Google Patents

治療的用途のためのフコシル化細胞の製造および凍結保存 Download PDF

Info

Publication number
JP2017525340A
JP2017525340A JP2016576062A JP2016576062A JP2017525340A JP 2017525340 A JP2017525340 A JP 2017525340A JP 2016576062 A JP2016576062 A JP 2016576062A JP 2016576062 A JP2016576062 A JP 2016576062A JP 2017525340 A JP2017525340 A JP 2017525340A
Authority
JP
Japan
Prior art keywords
cells
therapeutic
cell
fucosyltransferase
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016576062A
Other languages
English (en)
Japanese (ja)
Inventor
ウォルフ，ステファン，ディー．
Original Assignee
ターガザイム，アイエヌシー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ターガザイム，アイエヌシー． filed Critical ターガザイム，アイエヌシー．
Publication of JP2017525340A publication Critical patent/JP2017525340A/ja
Priority to JP2022017513A priority Critical patent/JP2022065029A/ja
Priority to JP2024061477A priority patent/JP7788486B2/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/125—Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0006—Modification of the membrane of cells, e.g. cell decoration
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/16—Physical preservation processes
    • A01N1/162—Temperature processes, e.g. following predefined temperature changes over time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01065—3-Galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase (2.4.1.65), i.e. alpha-1-3 fucosyltransferase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/724—Glycosyltransferases (EC 2.4.)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Materials For Medical Uses (AREA)
JP2016576062A 2014-07-07 2015-07-07 治療的用途のためのフコシル化細胞の製造および凍結保存 Pending JP2017525340A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022017513A JP2022065029A (ja) 2014-07-07 2022-02-07 治療的用途のためのフコシル化細胞の製造および凍結保存
JP2024061477A JP7788486B2 (ja) 2014-07-07 2024-04-05 治療的用途のためのフコシル化細胞の製造

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462021328P 2014-07-07 2014-07-07
US62/021,328 2014-07-07
PCT/US2015/039370 WO2016007506A1 (en) 2014-07-07 2015-07-07 Manufacture and cryopreservation of fucosylated cells for therapeutic use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022017513A Division JP2022065029A (ja) 2014-07-07 2022-02-07 治療的用途のためのフコシル化細胞の製造および凍結保存

Publications (1)

Publication Number Publication Date
JP2017525340A true JP2017525340A (ja) 2017-09-07

Family

ID=55064767

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016576062A Pending JP2017525340A (ja) 2014-07-07 2015-07-07 治療的用途のためのフコシル化細胞の製造および凍結保存
JP2022017513A Pending JP2022065029A (ja) 2014-07-07 2022-02-07 治療的用途のためのフコシル化細胞の製造および凍結保存
JP2024061477A Active JP7788486B2 (ja) 2014-07-07 2024-04-05 治療的用途のためのフコシル化細胞の製造

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022017513A Pending JP2022065029A (ja) 2014-07-07 2022-02-07 治療的用途のためのフコシル化細胞の製造および凍結保存
JP2024061477A Active JP7788486B2 (ja) 2014-07-07 2024-04-05 治療的用途のためのフコシル化細胞の製造

Country Status (9)

Country Link
US (3) US20170121673A1 (https=)
EP (1) EP3167046A4 (https=)
JP (3) JP2017525340A (https=)
KR (1) KR102505009B1 (https=)
CN (2) CN106687581A (https=)
AU (2) AU2015288052B2 (https=)
CA (1) CA2954534C (https=)
SG (1) SG11201610699XA (https=)
WO (1) WO2016007506A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020039326A (ja) * 2018-09-13 2020-03-19 極東製薬工業株式会社 間葉系幹細胞の凍害保護液とその利用
JP2021516052A (ja) * 2018-03-01 2021-07-01 フンダシオン パラ ラ インベスティガシオン ビオメディカ デル オスピタル グレゴリオ マラニョン 胸腺組織に由来する制御性ｔ細胞を入手する方法および免疫系障害における細胞免疫療法としての前記細胞の使用
JP2022065029A (ja) * 2014-07-07 2022-04-26 ターガザイム，アイエヌシー． 治療的用途のためのフコシル化細胞の製造および凍結保存
WO2022210514A1 (ja) 2021-03-30 2022-10-06 株式会社カネカ トリプシン阻害方法、それを用いた細胞製剤の製造方法
JP2022159210A (ja) * 2021-03-31 2022-10-17 株式会社カネカ 凍結接着性幹細胞の製造方法

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7332334B2 (en) 2003-04-18 2008-02-19 Oklahoma Medical Research Foundation Hematopoietic stem cells treated by in vitro fucosylation and methods of use
US20140161782A1 (en) 2008-06-09 2014-06-12 Targazyme, Inc. Augmentation of cell therapy efficacy including treatment with alpha 1-3 fucoslytransferase
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
JP6493692B2 (ja) 2013-03-15 2019-04-10 セルジーン コーポレイション 修飾されたｔリンパ球
SG11201705401YA (en) * 2014-12-30 2017-08-30 The Brigham And Women`S Hospital Inc Methods to improve cell therapy
IL309689B1 (en) * 2017-02-28 2026-02-01 Univ Central Florida Res Found Inc PM21 particles to enhance NK cell migration to the bone marrow
CN108617638B (zh) * 2017-03-22 2020-01-24 拜西欧斯（北京）生物技术有限公司 组织和/或细胞冻存保护液及其制备与应用
CN108925548A (zh) * 2017-05-24 2018-12-04 西比曼生物科技（香港）有限公司 一种冻存细胞制剂及细胞复苏方式
CN107012119B (zh) * 2017-05-31 2020-03-17 东莞市保莱生物科技有限公司 一种从骨髓中提取免疫细胞的方法
IL276365B2 (en) 2018-02-01 2023-10-01 Nkmax Co Ltd A method for the production of natural killer cells and a preparation for cancer treatment
CN108404219B (zh) * 2018-02-11 2020-09-29 华中科技大学 一种基于冷冻铸造技术的小口径人工血管及其制备方法
WO2019226618A1 (en) * 2018-05-22 2019-11-28 Nantkwest, Inc. Methods and systems for cell bed formation during bioprocessing
CN114615886A (zh) * 2019-08-29 2022-06-10 得克萨斯大学体系董事会 细胞冷冻保存培养基
CN114929249A (zh) * 2019-11-29 2022-08-19 Nkmax有限公司 产生自然杀伤细胞及其组合物的方法
US12188049B2 (en) 2020-04-14 2025-01-07 Tzu Chi University Methods for mobilizing stem cells
CN112913832A (zh) * 2021-01-27 2021-06-08 河南省华隆生物技术有限公司 一种滋养层细胞的保存方法
CN113151163A (zh) * 2021-04-23 2021-07-23 优牙生物科技(上海)有限公司 一种使用牙髓干细胞制剂修复子宫内膜损伤的方法
CN113396894A (zh) * 2021-07-06 2021-09-17 南方医科大学南方医院 适用于单位毛囊保存的复合冻存液及其制备方法和应用
CN116649328A (zh) * 2023-05-10 2023-08-29 杭州中赢生物医疗科技有限公司 一种人类活性免疫细胞冻存液及其冻存方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997039104A1 (en) * 1996-04-17 1997-10-23 Osiris Therapeutics, Inc. Cryopreservation and extensive subculturing of human mesenchymal stem cells
WO2005017115A2 (en) * 2003-08-11 2005-02-24 Mount Sinai School Of Medicine Of New York University Cord blood-derived hematopoietic progenitor cells
JP2007525164A (ja) * 2003-04-18 2007-09-06 リジュン シャ， インビトロフコシル化により処理された造血性幹細胞およびその使用法
JP2008539796A (ja) * 2005-05-20 2008-11-20 バイレクシス コーポレイション 初代細胞の形質導入
WO2009020201A1 (ja) * 2007-08-08 2009-02-12 Kyowa Hakko Kirin Co., Ltd. 単離された細胞集団
US20100311036A1 (en) * 2009-06-09 2010-12-09 University Of South Carolina Methods for Augmentation of Cell Cryopreservation
US20110091434A1 (en) * 2008-06-09 2011-04-21 America Stem Cell, Inc. Augmentation of cell therapy efficacy including treatment with alpha 1-3 fucosyltransferase
JP2013233147A (ja) * 2006-06-02 2013-11-21 Robert Sackstein 細胞表面グリカンを修飾するための組成物および方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789147A (en) 1994-12-05 1998-08-04 New York Blood Center, Inc. Method for concentrating white cells from whole blood by adding a red cell sedimentation reagent to whole anticoagulated blood
AU8005098A (en) 1997-06-06 1998-12-21 Governors Of The University Of Alberta, The Alpha1,3-fucosyltransferase of helicobacter pylori
US6461835B1 (en) 1998-09-03 2002-10-08 The University Of Oklahoma Fucosyltransferases, polynucleotides encoding fucosyltransferases, and transgenic mammal incorporating same
US20060210558A1 (en) 2000-10-18 2006-09-21 Robert Sackstein Hematopoietic cell selectin ligand polypeptides and methods of use thereof
CA2431901A1 (en) * 2000-12-14 2002-06-20 The University Of British Columbia Crystal structures of retaining glycosyltransferases
CA2474968A1 (en) * 2002-01-31 2003-08-07 Asahi Techno Glass Corporation Cryopreservation medium for primate embryo stem cells and cryopreservation method
US20100143969A1 (en) * 2005-03-24 2010-06-10 Neose Technologies, Inc. Expression of soluble, active eukaryotic glycosyltransferases in prokaryotic organisms
US8198045B2 (en) * 2006-04-19 2012-06-12 Biogenerix Ag Expression of O-glycosylated therapeutic proteins in prokaryotic microorganisms
JP5615509B2 (ja) * 2009-03-31 2014-10-29 北海道公立大学法人 札幌医科大学 フコシル化糖鎖産生細胞用物質送達担体
US8409838B2 (en) * 2009-06-02 2013-04-02 Regeneron Pharmaceuticals, Inc. Fucosylation-deficient cells
EP2480671B8 (en) * 2009-09-22 2015-10-28 ProBioGen AG Process for producing molecules containing specialized glycan structures
EP2507627A2 (en) * 2009-12-04 2012-10-10 Momenta Pharmaceuticals, Inc. Antennary fucosylation in glycoproteins from cho cells
CN102648708B (zh) * 2011-02-25 2014-08-13 深圳华大方舟生物技术有限公司 一种用于胚胎或细胞的冷冻液及其用途
CA2954534C (en) * 2014-07-07 2023-04-04 Targazyme, Inc. Manufacture and cryopreservation of fucosylated cells for therapeutic use

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997039104A1 (en) * 1996-04-17 1997-10-23 Osiris Therapeutics, Inc. Cryopreservation and extensive subculturing of human mesenchymal stem cells
JP2007525164A (ja) * 2003-04-18 2007-09-06 リジュン シャ， インビトロフコシル化により処理された造血性幹細胞およびその使用法
WO2005017115A2 (en) * 2003-08-11 2005-02-24 Mount Sinai School Of Medicine Of New York University Cord blood-derived hematopoietic progenitor cells
JP2008539796A (ja) * 2005-05-20 2008-11-20 バイレクシス コーポレイション 初代細胞の形質導入
JP2013233147A (ja) * 2006-06-02 2013-11-21 Robert Sackstein 細胞表面グリカンを修飾するための組成物および方法
WO2009020201A1 (ja) * 2007-08-08 2009-02-12 Kyowa Hakko Kirin Co., Ltd. 単離された細胞集団
US20110091434A1 (en) * 2008-06-09 2011-04-21 America Stem Cell, Inc. Augmentation of cell therapy efficacy including treatment with alpha 1-3 fucosyltransferase
US20100311036A1 (en) * 2009-06-09 2010-12-09 University Of South Carolina Methods for Augmentation of Cell Cryopreservation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GIANCOLA, R., ET AL.: ""Cell therapy: cGMP facilities and manufacturing."", MUSCLES, LIGAMENTS AND TENDONS JOURNAL, vol. 2, no. 3, JPN6019019466, July 2012 (2012-07-01), pages 243 - 247, ISSN: 0004465966 *
KNIBBS, R.N., ET AL.: ""Alpha(1,3)-fucosyltransferase VII-dependent synthesis of P- and E-selectin ligands on cultured T ly", J. IMMUNOL., vol. 161, no. 11, JPN6019019468, 1 December 1998 (1998-12-01), pages 6305 - 6315, ISSN: 0004043200 *
SHPALL, E.J., ET AL.: ""Novel cord blood transplant therapies."", BIOL. BLOOD MARROW TRANSPLANT., vol. Vol.17, Suppl.1, JPN6019019470, 2011, pages 39 - 45, ISSN: 0004465965 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022065029A (ja) * 2014-07-07 2022-04-26 ターガザイム，アイエヌシー． 治療的用途のためのフコシル化細胞の製造および凍結保存
JP2021516052A (ja) * 2018-03-01 2021-07-01 フンダシオン パラ ラ インベスティガシオン ビオメディカ デル オスピタル グレゴリオ マラニョン 胸腺組織に由来する制御性ｔ細胞を入手する方法および免疫系障害における細胞免疫療法としての前記細胞の使用
JP2020039326A (ja) * 2018-09-13 2020-03-19 極東製薬工業株式会社 間葉系幹細胞の凍害保護液とその利用
JP7072147B2 (ja) 2018-09-13 2022-05-20 極東製薬工業株式会社 間葉系幹細胞の凍害保護液とその利用
WO2022210514A1 (ja) 2021-03-30 2022-10-06 株式会社カネカ トリプシン阻害方法、それを用いた細胞製剤の製造方法
JP2022159210A (ja) * 2021-03-31 2022-10-17 株式会社カネカ 凍結接着性幹細胞の製造方法

Also Published As

Publication number Publication date
KR20170041204A (ko) 2017-04-14
CN114540266A (zh) 2022-05-27
JP7788486B2 (ja) 2025-12-18
EP3167046A4 (en) 2017-12-20
AU2015288052B2 (en) 2021-12-16
US20230014609A1 (en) 2023-01-19
KR102505009B1 (ko) 2023-03-03
AU2015288052A1 (en) 2017-02-02
SG11201610699XA (en) 2017-01-27
CN106687581A (zh) 2017-05-17
CA2954534A1 (en) 2016-01-14
JP2024099565A (ja) 2024-07-25
US20190062694A1 (en) 2019-02-28
AU2022201639A1 (en) 2022-03-31
WO2016007506A1 (en) 2016-01-14
CA2954534C (en) 2023-04-04
EP3167046A1 (en) 2017-05-17
US20170121673A1 (en) 2017-05-04
JP2022065029A (ja) 2022-04-26

Similar Documents

Publication Publication Date Title
JP7788486B2 (ja) 治療的用途のためのフコシル化細胞の製造
Bieback et al. Clinical protocols for the isolation and expansion of mesenchymal stromal cells
Bernardo et al. Mesenchymal stromal cells: a novel treatment modality for tissue repair
JP6266726B2 (ja) 放射線照射または化学物質による傷害を治療するための方法
JP2006525013A (ja) 血液幹細胞の数の増幅のための装置および方法
US20140205582A1 (en) Megakaryocyte progenitor cells for production of platelets
JP2017165757A (ja) 間葉系間質細胞集団およびそれを作成する方法
US20250297222A1 (en) Xeno-free generation of tissue-specific progenitor cells
JP7614106B2 (ja) 造血幹細胞の拡大
AU2012255112A1 (en) Mesenchymal stromal cell populations and methods of making same
CN107864627A (zh) 包含粘附基质细胞的方法和组合物
Taghizadeh Perinatal mesenchymal stem cell banking for umbilical cord blood transplantation and regenerative medicine
Vu et al. Off-the-shelf mesenchymal stem cell technology
菊地健志 et al. Study on methods of suppression of cell aggregation and utilization of pigs as cell source in mesenchymal stem cell therapy
Hosing et al. Mesenchymal stromal cells and umbilical cord blood transplantation
Antunes Developing an Advanced Therapy Medicinal Product (ATMP) for the treatment of GvHD
Weiss et al. Mesenchymal Stromal Cells Derived from Wharton's Jelly

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180706

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190522

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190528

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200428

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200721

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201028

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210316

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210614

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210813

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210915

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211005